WESTLAKE-CORPORATION
11.7.2024 21:17:27 CEST | Business Wire | Press release
This year, a particularly large number of plastics converters took part in the annual polymer producers’ assessment sponsored by the Polymers for Europe Alliance. All polymers users in Europe had until mid-May to vote and rate their polymer suppliers' performance during the past 12 months. Following this year's key criteria delivery reliability, circularity, quality, communication, innovation and commitment to the European Market, Westlake Vinnolit won the PVC category with 92% of the vote. "We are delighted with this great success and would like to thank our customers for their continued trust and inspiration," said Dr. Karl-Martin Schellerer, Senior Vice President, Westlake Performance and Essential Materials - Europe and Asia, and Managing Director of Westlake Vinnolit. "At the same time, this is the greatest incentive for us to continue to improve."
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711680182/en/
‘Supplier of the year for PVC’ and ‘Overall Award – Decarbonisation’ for Westlake Vinnolit: Ron Marsh, Chairman of the Polymers for Europe Alliance (left), congratulated Dr. Karl-Martin Schellerer, Senior Vice President, Westlake Performance and Essential Materials - Europe and Asia. (Photo: Polymers for Europe Alliance)
Furthermore, Westlake Vinnolit also won the ‘Overall Award – Decarbonization.’ “The PVC Award is a major accolade, surpassed only by being awarded the number one plastics supplier in terms of decarbonization,” said Schellerer, who received the awards and certificates from Ron Marsh, Chairman of the Alliance, and EuPC President Benoît Hennaut, at the ceremony that took place at the European Plastics Converters’ conference ‘A Circular Future with Plastics’ in Brussels. “The de-fossilization of plastics is an important building block in the effort to combat climate change and one of the biggest challenges for the industry. With our CO2-saving GreenVin® product line, we actively support our customers in helping them to reduce Scope 3.1 emissions and advance their sustainability goals.”
Vinnolit GreenVin® PVC is produced entirely with electricity from renewable energy sources, backed with European high-quality certificates for renewable energies (Guarantees of Origin / HKNs) and saves around 25% CO2 equivalents in comparison to conventionally produced ®Vinnolit PVC. The respective carbon footprint was calculated by Sustainable AG in accordance with the ISO 14067 standard and certified by TÜV Rheinland. GreenVin® bio-attributed PVC, in addition, uses renewable ethylene based on 2nd generation biomass, which increases the CO2 savings to around 90%, taking into account the biogenic CO2 fixation. Vinnolit GreenVin® bio-attributed PVC is mass-balanced and certified according to ISCC PLUS and REDcert2. The favorable product and processing properties desired by customers remain unchanged.
The Polymers for Europe Alliance was initiated by the European Plastics Converters association (EuPC) to provide factual public information on the status of the polymer supply situation in Europe and to engage in a constructive dialogue with the supply base. The initiatives of the Alliance also include the Polymer Producers Awards for Europe. In this Europe-wide customers’ satisfaction survey all users of polymers in Europe can rate their suppliers of the year.
ABOUT WESTLAKE VINNOLIT
As a leading manufacturer for PVC and an important partner for caustic soda, Westlake Vinnolit offers individual solutions for customers from a wide range of industries, such as the construction sector, the automotive industry, medical technology or pulp and paper production. As a manufacturer of high-quality PVC specialties, Westlake Vinnolit is a global market leader. At its headquarters in Ismaning near Munich and its four production sites in Burghausen, Gendorf, Knapsack and Cologne, 1,400 employees generate annual sales of more than €1 billion.
Westlake Vinnolit participates in the chemical industry's Responsible Care program for the continuous improvement of safety, health and environmental protection and supports VinylPlus®, the European PVC industry's voluntary commitment to sustainable development, as an "Official Partner" financially, ideally and through active participation. For more information visit www.westlakevinnolit.com
ABOUT WESTLAKE CORPORATION (WLK)
Westlake is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the Company's web site at www.westlake.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711680182/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom